<DOC>
	<DOC>NCT01374139</DOC>
	<brief_summary>The purpose of this study is to demonstrate the bioequivalence of the clinical tablet formulation (100 mg x 5) to the clinical capsule formulation (100 mg x 5) in healthy subjects under fed condition (Cohort 1) and to investigate the effect of a high-fat meal on the pharmacokinetics of bosutinib after administration of the proposed commercial tablet formulation (100 mg x 4) in healthy subjects (Cohort 2).</brief_summary>
	<brief_title>Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>Healthy male and/or female of non childbearing potential subjects between the ages of 21 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 Lead ECG or clinical laboratory tests. Pregnant or nursing women or women of childbearing potential.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Bosutinib</keyword>
	<keyword>Bioequivalence and Food Effect Studies</keyword>
</DOC>